Scholarlink

<p>Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, along with <i>Clostridioides difficile</i> (<i>C. difficile</i>) infection (CDI), are significant gastrointestinal disorders characterized by microbial dysbiosis and influenced by environmental factors. The success of current treatments for IBD and CDI, such as anti-inflammatory drugs and antibiotics, is limited by recurrence, antibiotic resistance, and disruption of healthy gut microbiota. These limitations have given rise to increased interest in probiotics as alternative, adjuvant therapies for both IBD and CDI. In this study, we evaluated the therapeutic potential of two probiotic strains, <i>Enterococcus faecium</i> HDS0288 and <i>Lactobacillus gasseri</i> HDS0266, in a dextran sodium sulfate (DSS) and CDI-induced colitis mouse model, which replicates key aspects of both IBD and CDI. Administration of the combination of <i>E. faecium</i> HDS0288 and <i>L. gasseri</i> HDS0266 led to significant improvements in intestinal barrier function, including increased goblet cell numbers and enhanced integrity of the mucus barrier, all of which contributed to&#xa0;the intestinal epithelium recovery. Our findings demonstrate that <i>E. faecium</i> HDS0288 and <i>L. gasseri</i> HDS0266 may serve as promising adjuvant therapies for the treatment of both IBD and CDI by promoting restoration of epithelial integrity and intestinal barrier function.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Restoration of the Mucosal Barrier by Lactobacillus gasseri HDS0266 and Enterococcus faecium HDS0288 in Dextran Sodium Sulfate and Clostridioides difficile-Induced Colitis Mice

  • 期刊论文

  • 发表日期：

    2025年10月22日

查看全文
  • Eunjung Kim,
  • Bobae Kim,
  • Haeun Kim,
  • Dongyeol Kim,
  • Ju Yeong Kim,
  • Jun Ho Choi,
  • Sun-Ju Oh,
  • Minjae Lee,
  • Woorim Park,
  • Hoyeon Kim,
  • Wilhelm H. Holzapfel,
  • Hongsup Yoon

摘要

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, along with Clostridioides difficile (C. difficile) infection (CDI), are significant gastrointestinal disorders characterized by microbial dysbiosis and influenced by environmental factors. The success of current treatments for IBD and CDI, such as anti-inflammatory drugs and antibiotics, is limited by recurrence, antibiotic resistance, and disruption of healthy gut microbiota. These limitations have given rise to increased interest in probiotics as alternative, adjuvant therapies for both IBD and CDI. In this study, we evaluated the therapeutic potential of two probiotic strains, Enterococcus faecium HDS0288 and Lactobacillus gasseri HDS0266, in a dextran sodium sulfate (DSS) and CDI-induced colitis mouse model, which replicates key aspects of both IBD and CDI. Administration of the combination of E. faecium HDS0288 and L. gasseri HDS0266 led to significant improvements in intestinal barrier function, including increased goblet cell numbers and enhanced integrity of the mucus barrier, all of which contributed to the intestinal epithelium recovery. Our findings demonstrate that E. faecium HDS0288 and L. gasseri HDS0266 may serve as promising adjuvant therapies for the treatment of both IBD and CDI by promoting restoration of epithelial integrity and intestinal barrier function.